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Introduction: Our previous clinical study demonstrated that the under-expression of FOXF2 is associated with early-
onset metastasis and poor prognosis of patients with triple-negative breast cancer. In this study, we further
characterized the role of FOXF2 in metastasis of basal-like breast cancer (BLBC) and underlying molecular mechanisms.
Methods: RT-qPCR, immunoblot, immunofluorescence and immunohistochemistry were performed to assess the
expression of genes and proteins in cell lines and tissues. A series of in vitro and in vivo assays was performed in the
cells with RNAi-mediated knockdown or overexpression to elucidate the function and transcriptional regulatory role of
FOXF2 in breast cancer.
Results: We found that FOXF2 was specifically expressed in most basal-like breast cells. FOXF2 deficiency enhanced
the metastatic ability of BLBC cells in vitro and in vivo. Additionally, FOXF2 deficiency induced the epithelial-mesenchymal
transition (EMT) of basal-like breast cells. Furthermore, we identified that TWIST1 is a transcriptional target of FOXF2.
TWIST1 was negatively regulated by FOXF2 and mediated the FOXF2-regulated EMT phenotype of basal-like breast cells
and aggressive property of BLBC.
Conclusions: FOXF2 is a novel EMT-suppressing transcription factor in BLBC. FOXF2 deficiency enhances metastatic
ability of BLBC cells by activating the EMT program through upregulating the transcription of TWIST1.Introduction
Breast cancer is the most frequently diagnosed cancer
among females [1]. Metastasis is the leading cause of
death in breast cancer patients. To develop distant meta-
static disease, the epithelial cancer cells need to undergo
a morphological change into a mesenchymal phenotype
to acquire migration and invasion ability [2]. Epithelial-
mesenchymal transition (EMT) is a program of switch-
ing polarized epithelial cells to migratory mesenchymal
cells [2]. The aberrant activation of the EMT program is
implicated in tumor progression, metastasis and acquisi-
tion of therapeutic resistance [2,3]. EMT-transcription* Correspondence: ymfeng@tijmu.edu.cn
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unless otherwise stated.factors (EMT-TFs) such as TWIST1, SNAIL1, SNAIL2,
ZEB1, ZEB2, Goosecoid and FOXC2, can trigger the
EMT program by directly or indirectly suppressing E-
cadherin expression [4-7]. TWIST1 is a member of the
basic helix-loop-helix (bHLH) transcription factor family
[8] and plays a pivotal role in the regulation of embryo-
genesis, gastrulation and mesoderm formation during
early embryonic development [9,10]. TWIST1 was found
to be frequently activated in a wide array of human can-
cers and is associated with poor prognosis [3,11]. TWIST1
induces the EMT program by downregulating E-cadherin
expression through indirect effects on the CDH1 pro-
moter [3].
Breast cancer is a heterogeneous disease. Based on their
gene expression profiles, breast cancers can be classified
into distinct molecular subtypes: normal breast-like, lu-
minal A, luminal B, human epidermal growth factor re-
ceptor 2 (HER2)-enriched, and basal-like [12]. Basal-like
breast cancer (BLBC) is less likely to express estrogen re-
ceptor (ER), progesterone receptor (PR) and HER2, whichThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(TNBC). Thus, BLBC shares many features with TNBC,
and the two terms are often used interchangeably [13]. In
addition to the triple-negative marker status, BLBC is
characterized by the expression of basal markers such as
cytokeratins (CK) 5/6, CK14, CK17 and epithelial growth
factor receptor (EGFR) in the clinic [12]. TNBC and/or
BLBC is recognized as a particularly aggressive subtype
and receives less benefit from targeted therapy [12].
Therefore, there is an urgent need to elucidate the mo-
lecular pathogenesis of TNBC and/or BLBC and develop
effective systemic therapies, especially molecular-targeted
therapy.
Recent reports have revealed that TNBC/BLBC is a
group of heterogeneous tumors [14]. BLBC also can be
divided into extraordinarily diverse basal-like A and
basal-like B subtypes [15]. The basal-like A cells have ei-
ther luminal-like or basal-like epithelial morphology,
while the basal-like B cells appear poorly differentiated
and possess more mesenchymal characteristics [15].
Thus, the basal-like B subtype is more aggressive than
the basal-like A subtype [15]. Due to the heterogeneity
of BLBC, it is important to identify the critical regula-
tory factors that are associated with aggressive pheno-
type of BLBC. It is well known that various embryonic
and mesenchymal EMT-TFs, including SNAIL1 [16],
SNAIL2 [17] TWIST1 [18], and Forkhead box (FOX)
transcription factor superfamily members FOXC1 [19],
FOXC2 [4] and FOXQ1 [20], contribute to the aggres-
sive phenotype of BLBC.
The mesenchymal regulator FOXF2 belongs to the
FOX transcription factor superfamily [21]. It is specific-
ally expressed in the mesenchyme adjacent to the epithe-
lium in organs derived from the splanchnic mesoderm
[22], and plays an important role in tissue homeostasis
through regulating epithelium-mesenchyme interaction
to maintain epithelium polarity [22]. Our previous clin-
ical study demonstrated that the under-expression of
FOXF2 is associated with early-onset metastasis and
poor prognosis of patients with TNBC, but not the prog-
nosis of non-TNBC patients [23]. This result suggests
that FOXF2 deficiency is involved in TNBC/BLBC me-
tastasis through regulating EMT. Recent studies have in-
dicated that FOXF2 is a potential tumor suppressor in
both prostate cancer [24] and breast cancer [25]. How-
ever, the role of FOXF2 in breast cancer metastasis and
the underlying molecular mechanisms remain largely
unknown.
In this study, we identified FOXF2 as a novel EMT-
suppressing transcription factor in BLBC and demon-
strated that it directly represses the transcription of
TWIST1. FOXF2 deficiency promotes metastasis of BLBC
cells through transcriptional upregulation of TWIST1 and
activation of EMT.Materials and methods
Cell culture
The human breast cancer cell lines MDA-MB-231,
BT549, MCF-7, BT474, ZR-75-30, SKBR-3 and MDA-
MB-453, immortalized non-tumorigenic basal-like mam-
mary epithelial cell lines MCF-10A and HBL100 were
obtained from American Type Culture Collection
(Manassas, VA, USA). MDA-MB-231-luc-D3H2LN (231-
Luc), a MDA-MB-231 subclone expressing luciferase, was
obtained from Caliper Life Sciences (Hopkinton, MA,
USA). MCF-10A cells were maintained in DMEM-F12
medium (Invitrogen, Gaithersburg, MD, USA) supple-
mented with 5% horse serum, 20 ng/mL EGF, 500 ng/mL
hydrocortisone, 10 μg/mL insulin and 100 ng/mL cholera
toxin. The other cells were cultured in DMEM-F12
(MCF-7 and MDA-MB-453) or RPMI 1640 (MDA-MB-
231, BT549, BT474, ZR-75-30, SKBR-3 and HBL100)
medium (Invitrogen) supplemented with 10% fetal bovine
serum (FBS; Invitrogen), 100 units/mL penicillin, and
100 mg/mL streptomycin (Invitrogen). All cell lines were
incubated in a humidified incubator at 37°C with 5% CO2
and grown into logarithmic phase and/or 80% confluence
for the experiments.
Lentiviral transduction of shRNA and transfection of
interfering RNA and plasmids
To obtain the stable FOXF2-knockdown cells, cells were
infected with the lentiviral vector expressing a short
hairpin RNA (shRNA) targeting the sequence GTCCTC
AACTTCAATGGGATT in the coding sequence region
of human FOXF2 gene (shFOXF2; Sigma-Aldrich, St
Louis, MO, USA; TRCN0000013959). A shRNA non-
targeting human and mouse gene was used as control
(shControl; Sigma-Aldrich; SHC002). The cells were se-
lected in 2 μg/mL puromycin to establish stable express-
ing shRNAs cells. For the rescue experiment, the stable
FOXF2-knockdown cells were transfected with shRNA-
resistant full-length FOXF2 plasmid (Genechem, Nanjin,
China), which has three nucleotide mismatches within
the target sequence of the shFOXF2 (GTCCTCAATTT
TAACGGGATT). To silence the expression of TWIST1,
the cells were transiently transfected with two independ-
ent small interfering RNAs (siRNAs) targeting the cod-
ing sequence region of human TWIST1 gene GGATCA
AACTGGCCTGCAA (si-TW#1) and GAACACCTTTA
GAAATAAA (si-TW#2; RiboBio Co., Guangzhou, China)
or a negative control siRNA (si-Control) using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
specifications. The human full-length FOXF2 cDNA was
amplified from a pEV-FOXF2 plasmid, which was a gift
from Professor Peter Carlsson (University of Gothenburg,
Department of Cell and Molecular Biology, Sweden), and
then was subcloned into the pcDNA3.1-HA vector (Invitro-
gen). The human full-length TWIST1 cDNA (Genechem)
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The cells were transfected with pcDNA3.1-HA-FOXF2
(FOXF2), pcDNA3.1-TWIST1 (TWIST1) or vector con-
trol (Invitrogen) using Lipofectamine 2000.
Reverse transcription quantitative polymerase chain
reaction
Total RNA isolation from cultured cells or tissues, reverse
transcription (RT) reactions, quantitative PCR (qPCR),
and the quantification of target gene expression were per-
formed as previously described [23].
Immunoblot, immunohistochemistry, and
immunofluorescence
The protocols for protein analysis by immunoblot, im-
munohistochemistry, and immunofluorescence were
performed as previously described [26]. The primary
antibodies were anti-E-cadherin, anti-N-cadherin, anti-
vimentin (BD Biosciences, Bedford, MA, USA), anti-
FOXF2 (Abnova, Aachen, Germany), anti-TWIST1,
anti-HA tag (Abcam, Cambridge, MA, USA), and anti-β-
actin (Sigma-Aldrich).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was per-
formed using a ChIP assay kit (EMD Millipore, Billerica,
MA, USA) according to the manufacturer’s instructions.
Anti-HA antibody (Abcam) was used for immunoprecip-
itation to enrich the promoter fragments containing pu-
tative FOXF2 binding site of target genes in MCF-10A
cells constitutively expressing HA-tagged FOXF2 (MCF-
10A-FOXF2). The isotype IgG (Abcam) was used as a
negative control. The primers for the amplification of
the TWIST1 promoter region containing a putative
FOXF2 binding site from −2120 to −2113 relative to the
transcription start site (TSS) were 5′-AGATTTCCTT
TACACTTTACCC-3′ (forward) and 5′-GCGAGTGTT
ATTTCTCCAGCGA-3′ (reverse). The primers for the
amplification of TWIST1 exon 1 (+408 to +841), which
served as a negative control, were 5′-CAGCGAGGAA
GAGCCAGACCG-3′ (forward) and 5′-GGAGGACCTG
GTAGAGGAAGT-3′ (reverse).
Luciferase reporter assay
The TWIST1 promoter region with (−2140 to +27) or
without (−2057 to +27) FOXF2 binding sites was ampli-
fied from human genomic DNA using the primers 5′-
AGTCCAATCATTCGATCTC-3′ (forward) and 5′-CTG
CAGACTTGGAGGCT-3′ (reverse), or 5′-ATAGCTGA
AGTGGAAAAGG-3′ (forward) and 5′-CTGCAGACTT
GGAGGCT-3′ (reverse) with Kpn I and Bgl II restric-
tion endonuclease recognition sites at the 5′-ends, re-
spectively. The fragments of the TWIST1 promoter were
cloned into the luciferase reporter gene plasmid pGL3-Basic (Promega, Madison, WI, USA). The pGL3 reporter
and pRL-TK plasmid were transiently co-transfected into
MCF-10A and BT549 cells for 48 h. The luciferase activity
of pGL3-TWIST1 (−2140/+27) or pGL3-TWIST1 (−2057/
+27) was normalized to Renilla luciferase activity.Cell proliferation
Cell proliferation ability was assessed using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Cells were seeded at a density of 2 × 103
cells/well in 96-well plates. On day 1, 2, 3, 4 and 5, the
cells were incubated with 10 μL MTT solution (5 mg/mL
in phosphate-buffered saline (PBS)) at 37°C for 4 h. After
removal of the medium, 100 μL DMSO was added to each
well and absorbance was measured at 570 nm.Cell invasion and migration assay
Cell invasion and migration ability in vitro were assessed
using Matrigel-coated and non-Matrigel-coated transwell
inserts (BD Biosciences) as described previously [26].Xenograft tumor assay
Twenty female 4- to 6-week-old severe combined im-
munodeficiency (SCID) mice were randomly divided into
two groups for the xenograft tumor assay. Then, 5 × 106
231-Luc cells infected with shFOXF2 (231-Luc-shFOXF2)
or shControl (231-Luc-shControl) were washed and har-
vested in 0.1 mL PBS and injected into the left lower ab-
dominal mammary fat pad of the SCID mice [27]. After
22 days, all mice were anesthetized using isoflurance and
injected intraperitoneally with 150 mg/kg D-luciferin/PBS.
The bioluminescent imaging was performed using a
Xenogen IVIS system (Caliper Life Sciences, Hopkinton,
MA, USA). The data of living image were expressed as
photon flux (photons per second). The tumor volumes
were measured by caliper at the indicated time and calcu-
lated using the formula (length x width2)/2 [28]. The sur-
vival time of mice was defined as the time interval
between the day of cell injection and the time of death or
sacrifice. The xenograft tumors, livers and lungs were har-
vested from xenograft mice at sacrifice. The tissues were
prepared for paraffin-embedded tissue section and
hematoxylin and eosin (H&E) staining or immunohisto-
chemistry staining. Two independent experiments were
performed with xenograft mice. In one experiment, the
mice died naturally to allow survival time calculations. In
the second experiment, the mice were sacrificed for dis-
section on day 21 after cell injection. The mouse xeno-
graft tumor assays were performed in accordance with
protocols approved by the Animal Ethics Committee of
Tianjin Medical University Cancer Institute and Hospital
(TMUCIH; Tianjin, China. No. 058).
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A total of 34 primary TNBC tissue specimens were ob-
tained from patients who underwent breast surgery in
TMUCIH. The use of these specimens was approved by
the Institutional Review Board of TMUCIH, and written
consent was obtained from all participants. All cases
were followed up over 3 years, and 30 cases were
followed up over 5 years. Disease-free survival (DFS)
was defined as the time interval between primary sur-
gery and any relapse (local-regional, contra-lateral and/
or distant), or the terminal time of follow-up without
any relapse events.
Independent data sets for validation of gene expression
levels in breast cancer cell lines and breast cancer tissues
The FOXF2 mRNA expression pattern in different sub-
types of breast cell lines was validated using the Gene
expression-based Outcome for Breast cancer Online
(GOBO) data sets [29].
Statistical analysis
Data from in vitro and in vivo experiments were pre-
sented as mean ± standard deviation (SD). Student’s t
test was used to compare differences between the ex-
perimental group and the control group. Fisher’s exact
test was used to compare the difference of metastatic in-
cidence between 231-Luc-shFOXF2 mice and the 231-
Luc-shControl mice. Spearman’s rank correlation was
used to analyze the correlation between FOXF2 and
TWIST1 mRNA levels in breast cancer tissues. Survival
plots were created using Kaplan-Meier analysis, and log-
rank test was used to assess statistical significance. P <0.05
was considered statistically significant.
Results
FOXF2 deficiency enhances migration and invasion of
basal-like mammary epithelial cells and BLBC cells in vitro
FOXF2 mRNA and protein expression levels in various
breast cell lines, including basal-like subtype cells MDA-
MB-231, BT-549, MCF-10A, HBL100 and non-basal-like
cells MCF-7, BT474, ZR-75-30, SKBR-3 and MDA-MB-
453, were measured by RT-qPCR and immunoblot, re-
spectively. The results showed that FOXF2 was highly
expressed in most basal-like cell lines and was less
expressed in non-basal-like cell lines (Figure 1A and B).
This expression pattern of FOXF2 in the basal-like (n = 14)
and non-basal-like (luminal; n = 25) subtype breast cell
lines was validated using GOBO data set analysis
(Figure 1C). The result confirmed that FOXF2 was fre-
quently and highly expressed in mesenchymal/myoepithe-
lium-like breast cells. Combining these results with our
previous finding that the under-expression of FOXF2 is
associated with early-onset metastasis and poor prognosis
of TNBC patients, but not the prognosis of non-TNBCpatients [23], we hypothesized that FOXF2 may play a role
in the metastasis of BLBC.
To investigate the roles of FOXF2 in regulating the in-
vasive potential of BLBC cells in vitro, the immortalized
non-tumorigenic basal-like mammary epithelial cell line
MCF-10A and the invasive BLBC cell lines MDA-MB-
231 was selected to establish stable FOXF2-knockdown
cells by infection with a lentiviral vector expressing a
FOXF2 shRNA (shFOXF2) or a non-target shRNA con-
trol lentiviral vector (shControl). The knockdown effi-
ciency of FOXF2 in these cells was shown in Figures 1D
and 2B. Boyden chamber transwell assays showed that
FOXF2 knockdown significantly promotes migration and
invasion of both the two cell lines (Figure 1E). To exclude
the off-target effects of the shFOXF2, we performed a res-
cue experiment by transfecting a shRNA-resistant full-
length FOXF2 in the stable FOXF2-knockdown cells. The
results showed that the effect of shFOXF2 on migration
and invasion of MCF-10A and MDA-MB-231 cells was
reversed (Figure 1E). Next, we transiently transfected
pcDNA3.1-FOXF2 in the BT549 cells, a BLBC cell line
with high invasiveness and less FOXF2 expression. The
overexpressed FOXF2 in the cells was shown in Figures 1D
and 2B. We observed that FOXF2 overexpression signifi-
cantly decreased the migration and invasion of BT549
cells (Figure 1E). In contrast with the role of promoting
cell migration and invasion, the cell growth curves showed
that FOXF2 knockdown significantly suppressed the pro-
liferation of MCF-10A and MDA-MB-231 cells and the
transfection of shRNA-resistant full-length FOXF2 res-
cued the effect of shFOXF2 on the proliferation of MCF-
10A and MDA-MB-231 cells (Figure 1F). Conversely,
FOXF2 overexpression in BT549 cells promoted the cell
proliferation (Figure 1F). In addition, we also tested the
functions of FOXF2 on luminal breast cancer cells by ec-
topically expressing FOXF2 in MCF-7 cells (see Figure
S1A in Additional file 1). However, the exogenous FOXF2
did not significantly affect the migration, invasion and
proliferation of MCF-7 cells compared to the control cells
(see Figure S1B and C in Additional file 1). Collectively,
these results suggest that FOXF2 deficiency enhances the
metastatic potential of basal-like mammary epithelial cells
and breast cancer cells but reduces cell proliferation.
FOXF2 deficiency enhances metastatic ability of BLBC
cells in vivo
To confirm the role of FOXF2 in metastasis of BLBC
cells in vivo, 231-Luc-shFOXF2 and 231-Luc-shControl
cells were injected into the mammary fat pad of female
SCID mice. The general physical condition of mice with
231-Luc-shFOXF2 cells (231-Luc-shFOXF2 mice) was
weaker compared to that of mice with 231-Luc-shControl
cells (231-Luc-shControl mice) by day 22 after injection
(Figure 3A). The weight of 231-Luc-shFOXF2 mice was
Figure 1 FOXF2 deficiency enhances migration and invasion of basal-like mammary epithelial cells and breast cancer cells in vitro.
(A) FOXF2 mRNA levels in the indicated cell lines were measured by RT-qPCR. The data were normalized to the expression of the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (B) The protein expression of FOXF2 in the indicated cells was detected by immunoblot.
(C) FOXF2 mRNA levels in different subtypes of breast cell lines were analyzed using an independent GOBO dataset. (D) FOXF2 mRNA levels in the
indicated cells were measured by RT-qPCR. Fold changes were relative to the mRNA expression of the control cells. (E) The migration and invasion
ability of the indicated cells were assessed by transwell assay. (F) Proliferation of the indicated cells was determined by MTT assay. Three independent
assays were performed in triplicate. The data were expressed as mean ± SD. **P <0.01. GOBO, Gene expression-based Outcome for Breast cancer Online;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; RT-qPCR, reverse transcription quantitative PCR; SD, standard deviation.
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Figure 2 FOXF2 deficiency enhances metastatic ability of BLBC cells in vivo. (A) Representative photos of the general physical condition of
xenograft mice injected with MDA-MB-231-Luc-shFOXF2 or the control cells on day 22 after injection. (B) The weights of xenograft mice injected
with MDA-MB-231-Luc-shFOXF2 (n = 4-10) or the control cells (n = 9-10) were measured at the indicated times. (C) Tumor volume of xenograft
mice injected with MDA-MB-231-Luc-shFOXF2 (n = 3-10) or the control cells (n = 9-10) at the indicated times. (D) Bioluminescence images of
primary xenograft tumor and metastatic tumor of xenograft mice injected with MDA-MB-231-Luc-shFOXF2 (n = 7) or the control cells (n = 10) on
day 22 after injection (Left) and the quantitation of metastatic photon flux of the lung, liver and whole body (Right). (E) Metastatic incidence of
xenograft mice injected with MDA-MB-231-Luc-shFOXF2 cells (n = 10) and the control cells (n = 10) on day 22 after injection. (F) Representative
photos (Top) and count (Bottom) of visible metastatic nodules in the liver of euthanized xenograft mice injected with MDA-MB-231-Luc-shFOXF2
cells (n = 10) and the control cells (n = 10) on day 21 after injection. (G) Representative H&E stained sections of lung and liver harvested from
xenograft mice. The arrows point to the metastatic foci in lung and liver. (H) Representative H&E-stained sections of primary tumor harvested
from xenograft mice. The arrows indicate that the cancer cells invaded into muscle (Left) and vasculature (Right). The selected areas of muscular
and vascular invasion are enlarged in the respective bottom panels. (I) Kaplan-Meier curves of the overall survival of xenograft mice (n = 10). Two
independent experiments were performed. The data were expressed as mean ± SD. *P <0.05; **P <0.01. BLBC, basal-like breast cancer; H&E,
hematoxylin and eosin; SD, standard deviation.
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Figure 3 FOXF2 deficiency induces EMT phenotype of basal-like mammary epithelial cells and BLBC cells. (A) Morphological photos of
the indicated cells (×200). (B) The protein expression of EMT markers and FOXF2 in the indicated cells was detected by immunoblot. (C) The protein
expression of EMT markers in the indicated cells was detected by immunofluorescence staining. (D) Vimentin expression in tissues of primary tumor,
lung metastases and liver metastases harvested from xenograft mice were stained by immunohistochemistry (×200). Arrows point to the metastatic
cancer cells. (E) MMP1, MMP2 and MMP9 mRNA levels in the indicated cells were measured by RT-qPCR. Fold changes were relative to the mRNA
expression of the control cells. Three independent assays were performed in triplicate. The data were expressed as mean ± SD. **P <0.01. BLBC, basal-
like breast cancer; EMT, epithelial-mesenchymal transition; RT-qPCR, reverse transcription quantitative PCR; SD, standard deviation.
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(Figure 3B). Consistent with the cell proliferation experi-
ments in vitro, 231-Luc-shFOXF2 mice had smaller xeno-
graft tumors than the 231-Luc-shControl mice (Figure 3C).At day 22 post injection, we performed in vivo bio-
luminescent imaging to monitor the metastasis using a
Xenogen IVIS system. The bioluminescent imaging and
metastatic photon flux analysis revealed that the 231-
Wang et al. Breast Cancer Research  (2015) 17:30 Page 8 of 14Luc-shFOXF2 mice suffered significantly more local inva-
sion and metastatic dissemination than the 231-Luc-
shControl mice, especially in the lung and liver metastases
(Figure 3D). The data revealed that 80% of 231-Luc-
shFOXF2 mice (8/10) suffered metastasis, whereas, 20% of
the control mice (2/10) suffered metastasis (Figure 3E).
Visible liver metastatic nodules were found in half of the
231-Luc-shFOXF2 mice (5/10), whereas none were found
in the livers of the 231-Luc-shControl mice (Figure 3F).
H&E staining confirmed that more metastatic foci formed
in the lungs and livers in 231-Luc-shFOXF2 mice than in
the control mice (Figure 3G). Moreover, there was more
muscle invasion in 231-Luc-shFOXF2 mice than in the
control mice. The tumors had blood vessel invasion in
the xenograft tumors of 231-Luc-shFOXF2 mice but not
in the tumors of the control mice (Figure 3H). A
Kaplan-Meier survival analysis revealed that the 231-
Luc-shFOXF2 mice had a significantly shorter survival
time than the 231-Luc-shControl mice (Figure 3I).
Taken together, these results indicate that FOXF2 defi-
ciency enhances the metastatic ability of BLBC cells and
leads to invasive and metastatic disease in vivo.
FOXF2 deficiency induces EMT phenotype of basal-like
mammary epithelial cells and BLBC cells
During mouse embryogenesis, FOXF2 is expressed in
the mesenchyme derived from the splanchnic mesoderm
adjacent to the ectoderm-derived epithelium and plays
an important role in tissue homeostasis through regulat-
ing epithelium-mesenchyme interactions to maintain the
epithelium polarity [22]. This expression pattern sug-
gests a potential role of FOXF2 in regulating EMT.
Therefore, we hypothesized that FOXF2 deficiency in
BLBC metastasis might be involved the EMT process.
We next investigate whether FOXF2 deficiency induces
EMT in BLBC cells. Compared with the MCF-10A-
shControl cells, FOXF2 knockdown transformed MCF-
10A cells from epithelial morphology into fibroblast-like
shape and caused cell scattering, and the expression of
shRNA-resistant full-length FOXF2 rescued the pheno-
type (Figure 2A). The detection of EMT markers re-
vealed that, compared to the control cells, FOXF2-
knockdown cells had reduced level of the epithelial
marker E-cadherin in MCF-10A cells (undetectable in
the MDA-MB-231 cell lines). Additionally, the FOXF2-
knockdown cells had elevated levels of the mesenchymal
markers vimentin in the MCF-10A, MDA-MB-231 cell
lines (Figure 2B). Immunofluorescence staining revealed
that the epithelial markers E-cadherin (undetectable in
MDA-MB-231) and β-catenin were lost from cell mem-
branes of FOXF2-knockdown cells and that the mesen-
chymal markers vimentin and fibronectin were increased
(Figure 2C). The expression of shRNA-resistant full-
length FOXF2 reversed the effect of shFOXF2 on theexpression of EMT markers (Figure 2B and C). Immu-
nohistochemistry staining confirmed that vimentin was
increased in primary xenograft tumors of 231-Luc-
shFOXF2 mice and metastases in lungs and livers
(Figure 2D). FOXF2 knockdown upregulated the expres-
sion of MMP1 and MMP9 in MCF-10A, MDA-MB-231,
and the expression of shRNA-resistant full-length
FOXF2 rescued the effect of shFOXF2 (Figure 2E). Con-
versely, FOXF2 overexpression in BT549 cells resulted in
a reversal of the EMT phenotype (Figure 2A, B and E).
However, the ectopic expression of FOXF2 in MCF-7
cells did not significantly affect the morphology (see
Figure S1D in Additional file 1) and the expression of
E-cadherin and vimentin (see Figure S1E in Additional
file 1). These observations indicate that FOXF2 func-
tions as an EMT suppressor in basal-like breast cells.
FOXF2 deficiency enhances metastatic ability of basal-
like mammary epithelial cells and BLBC cells through
inducing an EMT phenotype.
FOXF2 deficiency activates EMT program of basal-like
mammary epithelial cells and BLBC cells through
upregulation of EMT-TFs
To further investigate the mechanisms of how FOXF2
deficiency induces EMT phenotype, we examined the
mRNA expression of EMT-TFs including SNAIL1,
SNAIL2, TWIST1, ZEB1, ZEB2 and GSC (coding gene of
Goosecoid) in MCF-10A, MDA-MB-231 cells with or
without FOXF2 knockdown. The results showed that
FOXF2 knockdown upregulated TWIST1 and ZEB2 ex-
pression in both MCF-10A and MDA-MB-231 cells
(Figure 4A and B). Only ZEB1 and GSC were upregu-
lated in MDA-MB-231 cells and SNAIL2 was induced in
MCF-10A cells (Figure 4A and B). And the expression of
shRNA-resistant full-length FOXF2 rescued the effect of
shFOXF2 (Figure 4A and B). Conversely, FOXF2 overex-
pression in BT549 cells downregulated SNAIL2, TWIST1,
ZEB1, and GSC expression (Figure 4C). However, the ec-
topic expression of FOXF2 in MCF-7 cells did not signifi-
cantly change the expression of these EMT-TFs (see
Figure S1F in Additional file 1). These results indicate that
FOXF2 deficiency induced the EMT phenotype through
the activation of different EMT-TFs in the individual
basal-like breast cell lines.
FOXF2 binds to TWIST1 promoter and suppresses its
transcription
Because TWIST1 mRNA expression levels were com-
monly and negatively correlated with FOXF2 expression
in the basal-like breast cell lines (Figure 4A, B and C),
we investigated whether TWIST1 is a transcriptional tar-
get of FOXF2. First, we performed a BLAST search for
FOXF2 binding sites in the promoter region of the
TWIST1 gene. We found a putative FOXF2 binding site
Figure 4 FOXF2 deficiency activates EMT programming through upregulating EMT-TFs. (A, B and C) The mRNA expression levels of EMT-
TFs SNAIL1, SNALI2, TWIST1, ZEB1, ZEB2 and GSC in the indicated cells were measured by RT-qPCR. Fold changes were relative to the mRNA
expression of the control cells. Three independent assays were performed in triplicate. The data were expressed as means ± SD. *P <0.05; **P <0.01.
EMT, epithelial-mesenchymal transition; EMT-TFs, EMT-transcription factors; RT-qPCR, reverse transcription quantitative PCR; SD, standard deviation.
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−2120 to −2113 relative to the transcription start site
(TSS; Figure 5A). Subsequently, the binding of FOXF2
on the TWIST1 promoter region containing or lacking
the putative binding site was verified by ChIP assay in
MCF-10A cells. The results confirmed that FOXF2 can
bind to the TWIST1 promoter region containing the pu-
tative binding site but cannot bind to region lacking the
putative binding site (Figure 5B). Therefore, TWIST1 is a
candidate transcriptional target gene of FOXF2.
To further assess the regulatory activity of FOXF2 on
the TWIST1 promoter, we performed a luciferase re-
porter assay by transfecting pGL3-TWIST1 (−2140 to
+27) containing the putative binding site or pGL3-
TWIST1 (−2057 to +27) lacking the putative binding
site in MCF-10A cells with or without FOXF2 knock-
down. The results showed that the reporter activity of
pGL3-TWIST1 (−2140 to +27) was increased in MCF-
10A-shFOXF2 cells compared to the control cells, and
the expression of shRNA-resistant full-length FOXF2
rescued the effect of shFOXF2 (Figure 5C). The reporter
activity of pGL3-TWIST1 (−2057 to +27) was not sig-
nificantly changed in FOXF2-knockdown cells compared
to the control cells (Figure 5C). Conversely, FOXF2
overexpression in BT549 cells decreased the reporter ac-
tivity of pGL3-TWIST1 (−2140 to +27; Figure 5C). Fur-
thermore, the role of FOXF2 in negatively regulating
TWIST1 protein expression was confirmed using FOXF2
loss or gain of function in MCF-10A and BT549 cells by
immunoblot (Figure 5D) and immunofluorescence de-
tection (Figure 5E). Whereas, the ectopic expression of
FOXF2 in MCF-7 cells did not significantly change the
reporter activity of pGL3-TWIST1 (see Figure S1G in
Additional file 1) and TWIST1 expression (see Figure S1E
in Additional file 1). These results demonstrate that
FOXF2 suppress the transcriptional activity of the
TWIST1 promoter in basal-like breast cells. Cumulatively,
these data demonstrate that TWIST1 is a downstream tar-
get of FOXF2 and that FOXF2 suppresses TWIST1promoter activity and protein expression in basal-like
breast cells.
FOXF2 deficiency induces EMT phenotype of basal-like
mammary epithelial cells and aggressive property of
BLBC cells via upregulating TWIST1 expression
To further investigate whether TWIST1 mediates the
role of FOXF2 deficiency in inducing EMT in basal-like
breast cells, we knocked down TWIST1 expression in
MCF-10A-shFOXF2 cells by transiently transfecting two
independent TWIST1 siRNAs (si-TW#1 and si-TW#2),
respectively. The results showed that the FOXF2
knockdown-induced EMT phenotype of MCF-10A cells
was reversed by silencing TWIST1 expression. Also, the
expression of E-cadherin and vimentin (Figure 6A) was re-
versed, and epithelial morphology was restored (Figure 6B).
Additionally, the cells showed decreased migration and in-
vasion (Figure 6C). Next, we transiently transfected
pcDNA3.1-TWIST1 into MDA-MB-231 cells, and the
overexpressed TWIST1 in the cells was shown in
Figure 6D. We observed that TWIST1 overexpression re-
sulted in elevated levels of the mesenchymal markers
vimentin (Figure 6D) and enhanced migration and inva-
sion of the cells (Figure 6E). These results suggested that
TWIST may mediate FOXF2-regulated EMT phenotype
and aggressive property.
To provide in vivo evidence to illustrate the effect of
FOXF2 on metastasis was mediated by negatively regulat-
ing TWIST1 expression, we detected the TWIST1 protein
expression in primary tumors formed by inoculation of
MDA-MB-231-Luc shFOXF2 and MDA-MB-231-Luc
shControl cells in SCID mice by immunohistochemistry
staining. The result showed increased TWIST1 expression
in xenograft tumor of MDA-MB-231-Luc shFOXF2
comparing to the control tumor (Figure 6F). Furthermore,
we detected the mRNA levels of FOXF2 and TWIST1
mRNA in 34 cases of human primary TNBC tissues by RT-
qPCR. Consistent with the negative regulation of FOXF2
on the transcription of TWIST1, TWIST1 mRNA levels
Figure 5 FOXF2 binds to TWIST1 promoter and suppresses TWIST1 transcription. (A) The putative binding site of FOXF2 on the TWIST1
promoter region. (B) The binding of FOXF2 on the TWIST1 promoter region containing the putative binding site in MCF-10A cells was tested by a
ChIP assay. (C) Transcriptional activity of TWIST1 promoter in the indicated cells was assessed by a dual-luciferase reporter assay. (D) TWIST1
protein expression in the indicated cells was detected by immunoblot. (E) TWIST1 protein expression in the indicated cells was detected by
immunofluorescence staining. Three independent experiments were performed in triplicate. The data were expressed as means ± SD. *P <0.05;
**P <0.01. ChIP, chromatin immunoprecipitation; SD, standard deviation.
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tumor (Spearman’s rho = −0.421, P = 0.013; Figure 6G).
Then, the TNBC cases were divided into four groups based
on FOXF2 and TWIST1 mRNA levels: FOXF2high/TWIS-
T1low (n = 8), FOXF2high/TWIST1high (n = 8), FOXF2low/
TWIST1low (n = 8) and FOXF2low/TWIST1high (n = 10).
Kaplan-Meier analysis showed that the patients in the four
subgroups had distinct DFS: the patients in FOXF2high/
TWIST1low and FOXF2low/TWIST1high groups had the
best and poorest DFS, respectively (P = 0.002 between
both); the patients in the FOXF2high/TWIST1high and
FOXF2low/TWIST1low groups had moderate DFS (P =
0.687 between both); FOXF2high/TWIST1low group had
better DFS than FOXF2low/TWIST1low (P = 0.063) and
FOXF2high/TWIST1high (P = 0.143) groups; FOXF2low/
TWIST1high group had poorer DFS than FOXF2high/
TWIST1high (P = 0.089) and FOXF2low/TWIST1low (P =
0.149) groups (Figure 6H). This result suggests thatTWIST1low could contribute to the FOXF2high-suppressed
recurrence and metastasis of TNBC cells; conversely,
TWIST1high could facilitate the FOXF2low-induced recur-
rence and metastasis. Taken together, these results dem-
onstrated that TWIST1 functionally mediates the effect of
FOXF2 on EMTand metastasis in BLBC cells.
Discussion
The FOX transcription factors have tissue-specific ex-
pression patterns and play critical roles in embryogenesis
and tissue development through regulating tissue-
specific gene expression and cell differentiation [30]. Re-
cent evidence has demonstrated that the deregulation of
FOX factors is correlated with carcinogenesis and tumor
progression [21]. It is worth noting that several FOX
transcription factors link to the biological characteristics
of breast cancer. FOXA1 is highly expressed in luminal
subtype breast cancer [31], and its deficiency promotes
Figure 6 FOXF2 deficiency induces EMT of basal-like mammary epithelial cells via upregulation TWIST1 transcription. (A) The expression
of TWIST1 and EMT markers in the indicated cells was detected by immunoblot. (B) Morphology of the indicated cells (×200). (C) Photos (Lift)
and counts (Right) of migration and invasion of the indicated cells assessed by transwell assay (×200). Three independent experiments were
performed in triplicate. The data were expressed as mean ± SD. **P <0.01. (D) The expression of TWIST1 and vimentin in the indicated cells was
detected by immunoblot. (E) The migration and invasion ability of the indicated cells were assessed by transwell assay. Three independent
experiments were performed in triplicate. The data were expressed as mean ± SD. **P <0.01. (F) The TWIST1 protein expression in primary tumor
tissues harvested from xenograft mice of MDA-MB-231-Luc shFOXF2 and MDA-MB-231-Luc shControl cells was stained by immunohistochemistry
(×400). (G) The correlation of FOXF2 mRNA levels with TWIST1 mRNA levels in human primary TNBC tissues (n = 34; Spearman’s correlation rho = −0.421,
P = 0.013). (H) The correlation of combined FOXF2 and TWIST1 mRNA levels with the DFS of TNBC patients with FOXF2high/TWIST1low (n = 8), FOXF2high/
TWIST1high (n = 8), FOXF2low/TWISTlow (n = 8) and FOXF2low/TWIST1high (n = 10) was estimated by a Kaplan-Meier survival analysis. DFS, disease-free
survival; EMT, epithelial-mesenchymal transition; SD, standard deviation; TNBC, triple-negative breast cancer.
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FOXC2 [4], and FOXQ1 [20] are highly expressed in
basal-like subtype breast cancer, but are less present in
luminal subtype cancer. The ectopic expression of these
mesenchymal FOX factors in normal mammary epithe-
lial cells is able to induce EMT and lead to an aggressive
phenotype. FOXF2 is a mesenchymal transcription factor
and specifically expressed in the mesenchyme adjacent
to the epithelium and controls mesenchymal differenti-
ation to maintain the tissue homeostasis via epithelio-
mesenchymal interactions [22]. FOXF2 was found highly
expressed in benign prostatic hyperplasia and the transi-
tion zone of the normal prostate, where less suffer pros-
tate cancer [33,34]. In this study, we showed that FOXF2
is highly expressed in most basal-like breast cells. Since
basal-like breast cells are characterized by the basal gene
expression and with mesenchymal characteristics [15],
the expression pattern of FOXF2 in basal-like breast
cells is consistent with its nature of mesenchymal tran-
scription factors. We also found that FOXF2 deficiency
promoted the metastasis of BLBC cells, which is consist-
ent with our previous report that the under-expression
of FOXF2 is associated with early-onset metastasis and
poor prognosis of TNBC patients [23]. Our finding indi-
cates that FOXF2 may play a role in controlling the dif-
ferentiation state of basal-like breast cells and inhibits
the aggressive property of BLBC.
It is well known that a variety of embryonic and mes-
enchymal transcriptional factors function as EMT activa-
tors and are involved in the aggressive behavior of
BLBC, including SNAIL1 [16], SNAIL2 [17], TWIST1
[18], and FOX transcription factor family members
FOXC1 [19], FOXC2 [4] and FOXQ1 [20]. Most EMT-
TFs were identified as activators of EMT and promoters
of BLBC metastasis, while EMT suppressors are rarely
identified. FOXA2 is one such rare EMT suppressor
[35]. In this study, we showed that FOXF2 is a novel
EMT-suppressing transcription factor in basal-like breast
cells. FOXF2 deficiency enhanced the metastatic ability
of basal-like mammary epithelial cells and BLBC cells by
inducing an EMT phenotype. We observed that the de-
pletion of FOXF2 results in E-cadherin and β-catenin
loss from the cell membrane. It is known that during
EMT progression, the loss of E-cadherin expression
from adherent junction results in the release of β-
catenin into the cytoplasm. In addition, we observed that
the depletion of FOXF2 leads to a significant increase in
MMPs expression. Mesenchymal cells and the cancer cells
undergoing EMT secrete extracellular matrix (ECM)-de-
grading enzymes to facilitate invasion and motility [36].
Matrix metalloproteinase (MMP)2 [37], MMP3 [38] and
MMP9 [39] are able to induce EMT, and they trigger a
positive regulatory feedback loop that stabilizes EMT.
Therefore, the translocation of β-catenin translocationand upregulation of MMPs caused by FOXF2 deficiency
could lead to initiate vicious cycle of EMT.
TWIST1 is recognized as a critical modulator in EMT,
and its overexpression is able to trigger EMT phenotype
and tumor metastasis [3]. Thus, clarifying the regulatory
mechanism of TWIST1 expression would provide
insight into the regulatory pathway of TWIST1-induced
EMT programming and aid in developing molecular tar-
gets to inhibit tumor metastasis. It has been reported
that HIF-1 [40] and p65 [41] transcriptionally activate
TWIST1 expression to mediate hypoxia-induced and
tumor necrosis factor alpha (TNF-α)-induced EMT and
tumor metastasis, respectively. miR-720 [42] and miR-
106b [43] suppress TWIST1 expression by posttran-
scriptional regulatory mechanisms. In this study, we
identified FOXF2 as a transcriptional suppressor of
TWIST1. Therefore, we speculate that the two embry-
onic/mesenchymal transcription factors might act co-
operatively to maintain tissue homeostasis through
balancing the differentiation or dedifferentiation of mes-
enchymal/myoepithelial cells. FOXF2 deficiency could
lead to more dedifferentiation of myoepithelial cells and
an aggressive phenotype in BLBC via a TWIST1-
mediated pathway. This novel finding provided an un-
anticipated regulatory pathway of TWIST-induced EMT
and metastasis in BLBC.
In EMT programming, pleiotropic EMT-TFs form an
interaction network to enable them to work in concert to
regulate the EMT phenotype. The zinc-finger transcrip-
tion factors SNAIL1 [44], SNAIL2 [45], ZEB1 [46] and
ZEB2 [47] directly bind to the E-boxes of the CDH1 pro-
moter to repress its transcription. TWIST1 [3], Goosecoid
[48], and FOXC2 [4] trigger EMT by indirectly suppress-
ing CDH1 transcription. TWIST1 directly regulates
SNAIL2 transcription, and SNAIL2 is an essential medi-
ator of TWIST1-induced EMT [49]. TWIST1 can also in-
duce FOXC2 and SNAIL2 expression [7]. SNAIL1 has
been found to activate ZEB1 [2], FOXC2 and SNAIL2 ex-
pression [7]. In this study, we found that FOXF2 not only
negatively regulated TWIST1 expression but also regu-
lated the expression of SNAIL1 and SNAIL2, ZEB1,
ZEB2 and GSC in basal-like cell lines. Interestingly,
FOXF2 regulated TWIST1 expression in all the three cell
lines, but only regulated SNAIL2 in MCF-10A and BT-
549 cells, regulated ZEB1 and GSC in MDA-MB-231
and BT-549 cells, regulated ZEB2 in MCF-10A and
MDA-MB-231 cells. Therefore, in addition to activating
TWIST1 transcription, FOXF2 deficiency may induce
EMT through orchestrating different EMT-TFs expression
in the different basal-like breast cells.
In addition to BLBC, we also tested the effect of
FOXF2 on luminal breast cancer cells. However, we ob-
served that the ectopic expression of FOXF2 could not
significantly change the phenotype of luminal breast
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invasion, and slightly increase the transcription of
TWIST1. Our results suggest that there are different func-
tions of FOXF2 in basal-like and luminal cells. Based on
our current results, we speculate that mesenchymal
FOXF2 might be induced expression in luminal cells that
had undergone transdifferentiation into basal-like cells,
and when FOXF2 depletion during the progression of the
cells adapted mesenchymal characteristics could drive
these cells to possess more mesenchymal stem-like plasti-
city and aggressive phenotype by activating the transcrip-
tion of target gene TWIST1 and upregulating the
expression of other EMT-TFs. The regulatory mechanisms
of the different expression pattern and functions of
FOXF2 in basal-like and luminal breast cancer cells
should be further deeply investigated. Since FOXF2 plays
an essential role in the metastasis of BLBC cells, the ex-
ogenous administration of FOXF2 or interference of
FOXF2-TWIST1 pathway may be a promising therapeutic
strategy for improving the outcome of BLBC patients.
Conclusions
In conclusion, our study identified FOXF2 as a novel
EMT-suppressing transcription factor in BLBC. FOXF2
deficiency enhances metastatic ability of BLBC cells via
activating an EMT program by upregulating the tran-
scription of TWIST1.
Additional file
Additional file 1: Figure S1. FOXF2 overexpression was incapable of
inducing EMT of luminal breast cancer cells. (A) The protein expression of
FOXF2 in the indicated cells was detected by immunoblot. (B) The
migration and invasion ability of the indicated cells were assessed by
transwell assay. (C) The proliferation ability of the indicated cells was
determined by MTT assay. (D) Morphological photos of the indicated
cells (×200). (E) The protein expression of EMT markers in the indicated
cells was detected by immunoblot. (F) The mRNA expression levels of
EMT-TFs SNAIL1, SNALI2, TWIST1 and GSC in the indicated cells were
measured by RT-qPCR. Fold changes were relative to the mRNA expression
of the control cells. (G) Transcriptional activity of TWIST1 promoter in the
indicated cells was assessed by a dual-luciferase reporter assay. Three
independent assays were performed in triplicate. The data were expressed
as mean ± SD. n.s., P >0.05.
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